DSP-0692
/ Sumitomo Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 05, 2019
DSP-0692, a selective SCD inhibitor, enhances the anti-tumor activity of anti-PD1 antibody
(AACR 2019)
- "DSP-0692 induced PD-L1 and PD-L2 expression in CT-26 cells, indicating that it is one of a mechanism of restoration of the effect of anti-PD-1 antibody. Our data suggest that remodeling the lipogenic tumor microenvironment has potential to convert patients resistant to immunotherapy into those who may receive clinical benefit of immunotherapy."
IO Biomarker • PD(L)-1 Biomarker
1 to 1
Of
1
Go to page
1